Company Case Study

The next great revolution in infectious disease vaccination

Founders
Prof Adrian Hill (Head of the Jenner Institute for Vaccinology) Prof. Sarah Gilbert (Professor of vaccinology at Oxford)

CEO
Tom Evans

OSI Lead
Andrew McLean

Company
Vaccitech uses viral vectors, the most effective T-cell inducing technology in the world, to prevent & treat infectious diseases & cancers

Fuelling the next great revolution in infectious disease vaccination

From small beginnings in an laboratory in Oxford, to securing a £20m funding round from Sequoia and Google Ventures, Vaccitech is the story of a small team of brilliant British scientists changing the way the world vaccinates. As far as company missions go, Vaccitech’s is notable for its ambition. Led by CEO Tom Evans, its small team of eight formed in Oxford University’s Jenner Institute, are developing vaccinations for some of the world’s most prevalent and deadly diseases.

Perhaps most excitingly, it is already in Phase two clinical programs for universal influenza and prostate cancer, and a clinically approved vaccination for either of these two diseases could save millions of lives worldwide. It’s potentially one of the most important innovations in disease prevention since Edward Jenner’s first smallpox vaccine in the late eighteenth century.

Many startups say they are trying to ‘change the world’. Vaccitech is one of the very few that really could.

Back to Portfolio

Timeline

  1. 2015

    Dave Norwood, CEO of OSI meets with Adrian Hill and Sarah Gilbert at the Jenner Institute, Oxford.

    OSI approves £10 million seed round, with Andrew Mclean stepping in as interim CEO.

  2.  

    OSI, at its own risk, forms the company and provides it with a loan to begin these detailed preparations with a clinical trial.

  3. 2016

    Dave Norwood, CEO of OSI meets with Adrian Hill and Sarah Gilbert at the Jenner Institute, Oxford.

    OSI approves £10 million seed round, with Andrew Mclean stepping in as interim CEO.

  4.  

    OSI, at its own risk, forms the company and provides it with a loan to begin these detailed preparations with a clinical trial.